Gilead Sciences Inc is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines in areas of unmet medical need, particularly in infectious diseases, oncology, and inflammatory diseases. The company's mission is to advance the care of patients worldwide through groundbreaking research and development. Gilead Sciences Inc employs a strategy focused on leveraging its scientific expertise and robust pipeline to deliver transformative therapies, while also fostering collaborations and partnerships to enhance its operational capabilities and expand access to its life-saving treatments globally.

GILEAD SCIENCES INC

Gilead Sciences has shown impressive financial performance and growth potential, particularly through its leading HIV treatment, Biktarvy, which generated $13.4 billion in sales in 2024—a 13% year-on-year increase. This product accounted for nearly 46% of Gilead's total sales, which reached $28.8 billion. The company remains a strong dividend stock, offering...

Gilead Sciences Reports Strong Sales Growth and Expands HIV Treatment Options with Promising New Drug Application for Lenacapavir

Gilead Sciences is making waves with a remarkable 13% increase in Biktarvy sales, driving its total revenue to $28.8 billion. As the company prepares for a pivotal FDA decision on lenacapavir, can Gilead maintain its momentum in the competitive biotech landscape?